TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System
September 14 2020 - 6:55AM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that it established the first training center for the Senhance®
Surgical System in the Asia-Pacific region in Japan at the Saitama
Medical University International Medical Center in the Greater
Tokyo Area.
“The Asia-Pacific region has been a major contributor of new
system placements and surgical cases utilizing Senhance, a trend
that we would expect to continue into the future,” said Anthony
Fernando, president and chief executive officer at TransEnterix.
“We see the establishment of a dedicated surgical training center
at Saitama as an important milestone in enabling faster adoption of
Senhance in minimally invasive surgery throughout the region. Given
the growth and opportunity in the Asia-Pacific region, we are
pleased to provide local access to training for Asian surgical
teams, which is particularly important in the current environment
where travel to the US or EU is more difficult.”
“We were the first center in Japan to begin a clinical program
utilizing the Senhance System to provide advanced digital surgical
technology in treating our patients, and have grown our clinical
expertise using the system in multiple surgical disciplines,” said
Dr. Isamu Koyama, Senior Managing Director of Saitama Medical
University. “This training center will allow surgeons from
throughout Japan and the region to collaborate and develop their
skills on the Senhance System as they begin utilizing this
technology in their own institutions.”
The Asia-Pacific laparoscopy device market is expected to grow
at a cumulative average growth rate of 8.2% from $1.26 billion in
2019 to $1.87 billion by 2024, according to Market Data Forecast,
Inc. This expected growth, the significant benefits of digital
laparoscopy, and the establishment of the Japanese Training Center
is expected to drive increased utilization of our six system
installations in the Asia-Pacific region and encourage further
adoption of our technology in additional hospitals. In 2020, the
number of clinical case procedures in this region utilizing the
Senhance System has surpassed the number of procedures in all of
2019, despite the impact of the COVID-19 pandemic.
The Senhance System is the first and only digital laparoscopic
surgical platform designed to maintain laparoscopic MIS standards
while providing digital benefits such as haptic feedback, robotic
precision, comfortable ergonomics, advanced instrumentation
including, 3mm microlaparoscopic instruments, eye-sensing camera
control and reusable standard instruments to help maintain
per-procedure costs similar to traditional laparoscopy. The
Senhance Surgical System was approved for use by the Japanese
Ministry of Health, Labor and Welfare (MHLW) in 2019, and has the
broadest procedural reimbursement of any abdominal robotic surgery
platform in Japan, which applies to 98 benign and malignant
laparoscopic procedures across general, colorectal, gynecologic,
pediatric and urologic surgeries at reimbursement rates equivalent
to traditional laparoscopy in Category A1.
About Saitama Medical University International Medical
Center
Saitama Medical University International Medical Center was
established in April 2007 with the objective of contributing to
regional and Japanese medicine, aiming to create an internationally
competitive world-class hospital. Their mission is to cover all
areas of Saitama prefecture, to be dedicated in highly specialized
medical service for cancer and heart disease, and to provide
advanced critical and emergency medical care. The medical center is
affiliated with Saitama Medical University Medical Hospital, and is
one of the top ranked hospitals in Japan. Saitama Medical
University International Medical Center is the first university
hospital in Japan to be Joint Commission International (JCI)
accredited.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit (ISU™) that enables
augmented intelligence in surgery. The Senhance® Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Company’s first training center in Japan. These
statements and other statements regarding our future plans and
goals constitute "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the
Company’s first training center in Japan at the Saitama Medical
University International Medical Center will be an important
milestone in enabling faster adoption of Senhance in minimally
invasive surgery throughout the region, whether the training center
will allow surgeons from throughout Japan and the region to
collaborate and develop their skills on the Senhance System as they
begin utilizing this technology in their own institutions and
whether the expected growth, significant benefits of digital
laparoscopy and the establishment of the Japanese Training Center
will drive increased utilization of our installed systems in the
Asia-Pacific region and encourage further adoption of our
technology in hospitals. For a discussion of the risks and
uncertainties associated with TransEnterix's business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2019, filed with the SEC on March 16, 2020 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200914005210/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com
or
Media Contact: Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Apr 2023 to Apr 2024